Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Is Lululemon a buy, sell or hold?

Lululemon Athletica Inc. (NDAQ: LULU) has seen a recent dip in its share price, declining to its lowest level in four years one day before the company’s 2024 Summer Olympic apparel debuted on Team Canada athletes in the opening ceremonies of Paris 2024...
Coreena Robertson | August 8, 2024 |

Where’s the Bottom? – Cycles Paint A Clear Picture

Has the selloff ended? When will it end? What will the bottom look like and am I at risk of taking further losses? What should I do? Do you want to take a guess at how many of our friends and family members are calling us over the past week or so asking these questions? Pe...
Chris Vermeulen | March 13, 2020 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

NASDAQ Set to Fall 1000pts In Early 2020, and What it Means for Gold

One of our most interesting predictive modeling system is the Adaptive Dynamic Learning (ADL) price modeling system. It is capable of learning from past price data, building price DNA chains and attempting to predict future price activity with a fairly high degree of accuracy....
Chris Vermeulen | January 6, 2020 |

Progress for radiology drugs and medical imaging company

Voyageur Pharmaceuticals ( TSXV:VM ) ( OTC:VYYRF ) is focused on vertically integrating the barium, iodine and carbon contrast imaging market – think radiology drugs and medical imaging. Its business plan is set to generate immediate cash flow by partnering with thir...
Shoran Devi | June 12, 2023 |

Targa Exploration raising more than $1.3M for Opinaca Project

Targa Exploration Corp. (CSE:TEX) is raising more than C$1.3 million in a non-brokered private placement The financing raise consists of hard dollar and charity flow-through units Targa completed the first tranche of the private placement March 28 for gr...
Coreena Robertson | April 5, 2024 |

The Revolutionary Co. That’s Breaking Through the Blood Brain Barrier

(Click image to play video) Delivery of therapeutics across the blood-brain barrier (BBB) and into the brain has been the single greatest challenge to treating hundreds of common and rare neurological diseases, including brain cancers, neurodegenerative diseases...
Dave Jackson | December 1, 2020 |

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications

This California company expects results from clinical trials in liver disease and psoriasis in 2019. In a March 8 research note, H.C. Wainwright & Co. analyst Ed Arce reported that DURECT Corp. (DRRX:NASDAQ) continues advancing clinical trials evaluating its lead prod...
Streetwise Reports | March 14, 2019 |
1 2 3 4 5